Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ViaCyte revenue
ViaCyte's revenue is $25.0 million.
What is ViaCyte's revenue?
- ViaCyte has 105 employees, and the revenue per employee ratio is $238,095.
- ViaCyte peak revenue was $25.0M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
ViaCyte financing
ViaCyte received early financing of $20.0M on 2006-05-03.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $20M | 05/2006 |
| Series C | $25M | 07/2007 |
| Series C | $10.6M | 07/2013 |
| Series C | $5.4M | 08/2014 |
| Series Unknown | $20M | 08/2014 |
| Grant | $16.6M | 09/2014 |
| Grant | $3.9M | 07/2016 |
| Series Unknown | $10M | 05/2017 |
| Grant | $1.4M | 12/2017 |
| Convertible Note | $10M | 09/2018 |
| Series D | $80M | 11/2018 |
| Series D | $32.6M | 03/2020 |
| Series D | $53.9M | 04/2021 |
ViaCyte investors
| Investors | Security type |
|---|---|
| Headland Ventures LP | Series Unknown |
| Sanderling Ventures | Series Unknown |
| Johnson & Johnson Development Corporation | Series Unknown |
| The Vertical Group | Series Unknown |
| Asset Management Ventures | Series Unknown |
| BD Venture Limited | Series Unknown |
| DFJ Portage Ventures | Series Unknown |
| Pacific Horizon Ventures | Series Unknown |
| Johnson & Johnson Development Corporation | Series C |
| Sanderling Ventures | Series C |
| Asset Management Ventures | Series C |
| Pacific Horizon Ventures | Series C |
| Johnson & Johnson Development Corporation | Series C |
| Sanderling Ventures | Series C |
| JOHNSON & JOHNSON INNOVATION | Series Unknown |
| California Institute for Regenerative Medicine | Grant |
| W L Gore & Associates | Series Unknown |
| JDRF | Series Unknown |
| Asset Management Partners | Series Unknown |
| California Institute for Regenerative Medicine | Grant |
| W L Gore & Associates | Convertible Note |
| Sanderling Ventures | Series D |
| Bain Capital Life Sciences | Series D |
| RA Capital Management | Series D |
| TPG | Series D |
| Sanderling Ventures | Series D |
| Bain Capital Life Sciences | Series D |
| TPG Capital Asia | Series D |
| RA Capital Management | Series D |
| Sanderling Ventures | Series D |
| Artis Ventures | Series D |
| Invus | Series D |
| Bain Capital Life Sciences | Series D |
| TPG Capital Asia | Series D |
| Adage Capital Management | Series D |
| RA Capital Management | Series D |
| Asymmetry Ventures | Series D |
ViaCyte competitors
ViaCyte's top competitor, Cabot Microelectronics, earned an annual revenue of $1.2B.
ViaCyte's smallest competitor is SymbioCellTech with revenue of $220.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Intl Stem Cell | - | $7.1M | 20 | - |
| Minerva Biotechnologies | - | $2.4M | 24 | - |
| InGeneron | - | $4.4M | 32 | - |
| Semma Therapeutics | - | $34.9M | 75 | - |
| SymbioCellTech | - | $220,000 | 3 | - |
| Sernova | - | $1.6M | 15 | - |
| Encellin | - | $440,000 | 12 | - |
| Liveyon | - | $1.9M | 75 | - |
| Brewer Science | - | $75.0M | 200 | - |
| Cabot Microelectronics | - | $1.2B | 4,500 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
ViaCyte highest paying jobs
Zippia gives an in-depth look into the details of ViaCyte, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ViaCyte. The employee data is based on information from people who have self-reported their past or current employments at ViaCyte. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ViaCyte. The data presented on this page does not represent the view of ViaCyte and its employees or that of Zippia.
ViaCyte may also be known as or be related to ViaCyte, ViaCyte Inc., ViaCyte, Inc., Viacyte and Viacyte, Inc.